Login
← Go Back
Divi's Laboratories
DIVISLAB · Pharma > Pharmaceuticals & Drugs · Chairman: Ramesh BV Nimmagadda · MD: Murali K Divi · Listing date: March 12, 2003 · Employees: 16818 · Hyderabad · http://www.divislabs.com
Stock Price vs Company Growth
1d
0.1%
1w
1.4%
1m
10.7%
3m
19.6%
6m
13.0%
1y
52.0%
5y
23.6%
10y
23.5%
all
23.8%
🤔 How to analyze this graph?
Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price
₹ 6,723 0.1%
4,942
6,860
Company Overview
Sales
9,360 Cr
Growth: 15.1%
Profit after Tax
2,191 Cr
Growth: 6.0%
Large Cap
1,78,468 Cr
P/E: 81.5x
Industry P/E: 34.4x
Fundamentals
Sales (Cr) ₹ 9,360
Growth 15.1%
EBITDA 31.7%
P/S 19.1x
Dividend 0.6%
P/E 81.5x
Book Value ₹ 564
PEG Ratio 5.4x
ROE 15.0%
P/B 11.9x
Shareholding Pattern
Institutions
Sbi Mutual Fund
4.49 %
Qualified Institutional Buyer
3.57 %
Axis Mutual Fund Trustee Ltd
3.37 %
Government Pension Fund Global
1.29 %
Life Insurance Corporation Of India
1.15 %
Promoters
Nilima Prasad Divi
20.34 %
Divi Satchandra Kiran
20.34 %
Divi Swarna Latha
5.27 %
Divi'S Biotech Private Limited
3.01 %
Murali Krishna Prasad Divi
2.85 %
Others
Increase    Decrease    No change
Company Profile Detailed
The Company manufactures Generic APIs, Nutraceutical Ingredients and offers Custom Synthesis of APIs to Big Pharma providing a competitive advantage over the entire life cycle of the products.
Belongs to (49 Indices) view more
Investors (132)
credit.s...
valiant....
the.mtbj...
Followers (42)
deepak
jayapras...
nitin2